Research progress on immunohistochemical diagnostic markers for malignant pleural mesothelioma

VernacularTitle:恶性胸膜间皮瘤免疫组织化学诊断标志物的研究进展
Author: Yuanqian PU ¹ ; Yepin ZHANG ; Wei XIONG
Author Information

1. 大理大学基础医学院生物化学与分子生物学教研室，大理　671000
Keywords: Mesothelioma; Malignant pleural mesothelioma (MPM); Immunohistochemistry (IHC); Diagnostic markers
From: Chinese Journal of Industrial Hygiene and Occupational Diseases 2023;41(11):869-875
CountryChina
Language:Chinese
Abstract: Malignant pleural mesothelioma (MPM) is a malignant tumor originating from the pleura, characterized by insidious onset, strong local invasiveness, short survival period, and poor prognosis. Clinical diagnosis is of paramount importance for the treatment and prognosis of MPM. Currently, the gold standard for diagnosing MPM is the results of histopathological examinations. Immunohistochemistry (IHC) is an effective auxiliary method in pathological diagnosis. Preliminary examinations can use two positive markers and two negative markers to distinguish pleural metastatic tumors, with additional antibodies selected based on differential diagnosis. The combined use of IHC markers plays a crucial role in the differential diagnosis between MPM and other tumors. This article primarily introduces commonly used IHC markers in MPM and the research progress of novel IHC markers in screening and differential diagnosis, aiming to provide reference for the clinical diagnosis and treatment of MPM.